203-789-7645 innovate@yale.edu

Speaker Bios

Dr. Brenna Bry

Brenna H. Bry, Ph.D, is Professor Emerita at Rutgers,The State University of New Jersey. Findings from Dr. Bry's ongoing studies of risk and protective factors have supported the development, evaluation, and dissemination of her manualized preventive intervention-- the school-based Achievement Mentoring Program. Because the program has been designated by the U.S. Department of Education's Safe and Drug-Free Schools Program and the U.S. Center for Substance Abuse Prevention as an effective strategy, Dr. Bry has commercialized her program for use by schools and government agencies.

Dr. Bridget Martell

Dr. Martell has over 15 years of experience in the Pharmaceutical/Biotechnology industry as a Chief Medical Officer, and strategic/scientific advisor, working across all stages of clinical drug development. She is currently Managing Director and founder of BAM Consultants, LLC, a clinical/scientific advisory firm and prior to this, was Senior Vice President of New Product Development and Chief Medical Officer of Juniper Pharmaceuticals, a public company with a focus on Women’s Health therapeutics. Dr. Martell’s previous work included leading medical affairs at Purdue Pharma and clinical development and medical affairs at Pfizer as the Biosimilars Medical Head. She also held senior clinical development roles at other business units within Pfizer’s biopharmaceutical businesses. She began her clinical investigation career at Yale with a Career Development Award and as a Faculty Auditor in the Robert Wood Johnson Clinical Scholar conducting the first therapeutic cocaine vaccine trial for adjunctive treatment for cocaine dependence.

Narath Carlile, MD, MPH

Dr. Carlile is the Chief Medical Information Officer for ACT.md, a practicing physician in Internal Medicine at Brigham and Women's Hospital in Boston, and an instructor at Harvard Medical School. Prior to joining ACT.md, he has been involved in a number of informatics projects including developing an open source paging system for hospitals in Africa, mobile decision support for community health workers in Mexico, interactive voice response systems for medical clinics and educational software used internationally. He has previously served as a director of engineering, and as the director of a software development center.

Vasum Peiris, MD, MPH, FAAP, FACC, FASE

As Chief Medical Officer for Pediatrics and Special Populations, Dr. Peiris serves as the Center’s senior clinical expert on pediatrics and pediatric medical device issues. He provides clinical and executive leadership on Center policies associated with medical devices intended for use in the pediatric populations. He engages and develops Agency-wide and cross-Agency initiatives that serve pediatrics and special populations. He leads the Center's outreach to facilitate the development of new and modified devices to address the needs of pediatric and special populations, explains relevant Agency/Center activities, policies and decisions, and solicits feedback. He also leads the Center’s efforts with respect to the development, assessment, regulation and safe use of pediatric medical devices. He has previous experience as a Medical Director and Chief at the Pediatric and Adult Congenital Cardiac Exercise Stress Laboratory at the University Medical Center at TTUHSC.

Jordan Amadio, M.D., M.B.A.

A practicing neurosurgeon and neuroscientist, Dr. Amadio was educated at Princeton, MIT, Harvard Medical School, and Harvard Business School. In 2014, he was granted the American Medical Association's Excellence in Medicine Leadership Award and was named “40 under 40” by the Atlanta Business Chronicle and MedTechBoston. He serves as Chief Resident in Neurosurgery at Emory University and is the Innovation Fellow for the Congress of Neurological Surgeons. He is a passionate advocate for investment in neurotechnology.

Eric Buehrens

Eric Buehrens has enjoyed a varied career as executive, consultant, and senior advisor in healthcare and higher education, government and private industry, and as an instructor in Health Policy and Management at the Harvard School of Public Health. He has been an executive in academic medicine for 20 years, serving as executive dean for administration at Harvard Medical School, deputy provost for administration at Harvard University, executive vice president, COO, and interim CEO of the Beth Israel Deaconess Medical Center, and as EVP and COO of Reliant Medical Group, a multi-specialty physician group practice.

Rahul Rajkumar

Rahul Rajkumar, MD, JD, was named Senior Vice President and Chief Medical Officer for CareFirst BlueCross BlueShield in 2016. He assists in overseeing operation of the company's Patient-Centered Medical Home and Total Care and Cost Improvement programs, and as part of CareFirst's Medical Affairs division, plays a role in developing medical policy for the region's largest insurer. Prior to joining CareFirst, Dr. Rajkumar served as Deputy Director at the Center for Medicare and Medicaid Innovation. He holds a Bachelor of Arts degree in History from Yale University, a doctorate degree of medicine (MD) from Yale’s School Of Medicine, and a doctorate degree of law (J.D.) from Yale’s School Of Law. Dr. Rajkumar is an attending physician at the Veterans Affairs Hospital in Washington, D.C., and is a Fellow of the American College of Physicians.

Lynn Hamilton

Lynn Hamilton is the Chief Commercial Officer at Talkspace – Online Therapy. She is a Senior healthcare executive with broad and deep experience developing new revenue channels, marketing and growing existing programs and forging client relationships. She has demonstrated internal and external leadership across multi-disciplinary teams. She effectively partners with key stakeholders including provider, payer, employer, federal, and pharmacy organizations. Lynn is an expert at fostering interpersonal relationships, understanding clinical and business challenges, and developing effective and efficient solutions, and has the ability to quickly clarify issues, develop strategies to tackle them, and advocate solutions and mobilize cross-functional resources to meet healthcare and business objectives while consistently achieving superior outcomes. She has a mission driven focus on quality outcomes in healthcare.

James G. Boyle

Jim Boyle is a co-founder and the Managing Director of the Yale Entrepreneurial Institute (YEI), a business/educational unit within Yale University that was formed with the mission of mentoring students with new venture ideas and that has expanded to include the development of faculty ventures. Prior to forming YEI, Boyle was responsible within the Office of Cooperative Research (OCR) for the licensing and venture startup of a number of engineering-based technologies. Before joining OCR, he developed and actively managed the University’s largest corporate research alliance, managing a large array of both Yale and external scientists in bioimaging-based collaborations. Earlier, Boyle co-founded and grew a predictive analytics consulting practice, providing both technical and pricing guidance on new product development to a wide array of Fortune 1000 companies in the scientific equipment industry. Boyle began his entrepreneurial career while still a Yale graduate student, developing novel instruments for characterizing trace biomolecules with the support of the National Institutes of Health, and later commercializing these devices through a wide array of OEM partnerships as part of a Yale startup.

Scott K. Dessain, M.D, Ph.D.

Dr. Dessain is an Associate Professor at the Lankenau Institute for Medical Research in Wynnewood PA. He received M.D. and Ph.D. degrees from Yale University in 1994. He pursued post-graduate medical training in Internal Medicine at Brigham and Women’s Hospital, followed by a fellowship in Medical Oncology at Dana Farber/Partners Cancer Care Boston, MA. His post-doctoral training was with Dr. Robert Weinberg at the Whitehead Institute in Cambridge, MA, at which time he devised novel techniques to efficiently clone native human antibodies. Following his fellowship, he spent 2 years as an instructor at the Massachusetts General Hospital in Boston, specializing in bone marrow transplantation and malignant hematology, and then joined the faculty of the Cardeza Foundation for Hematologic Research at the Thomas Jefferson University in Philadelphia. He co-founded Immunome in 2008. He has contributed to 29 published articles and two U.S. patents. Dr. Dessain has received K08 and R01 research grants from the National Institute of Health. He is Board-Certified in Medical Oncology and attends at the Lankenau Hospital in Wynnewood, PA.

Scott Fishman, MD

Scott has over 30 years’ experience in healthcare marketing research and commercial analysis. As CEO of Research by Design, a firm he started in 1989, Scott directed the evolution of the company from a bedroom startup to one of the most successful and prominent firms in the healthcare research industry. Under Scott’s guidance, RBD became a key consulting resource for virtually every major pharmaceutical company, as well as a wide range of biotechnology and medical device manufacturers and healthcare advertising agencies.

Following the sale of his firm to a global holding company in 2006, Scott founded Ethos LifeScience Advisors, the parent to Envisage Solutions. Scott also co-developed, launched and serves as consulting Program Executive for the Commercialization Acceleration Program (CAP) at the Wharton Small Business Development Center. CAP provides due diligence to Technology Transfer Offices, Incubators and VCs to support commercial development of intellectual property.

Victor Prikhodko, Scientific Program Manager, NIDA, OD, OTIPI

Victor Prikhodko is a Scientific Program Manager within the Office of Translational Initiatives and Program Innovations (OTIPI) which supports the National Institute on Drug Abuse (NIDA) and administers a $30M/Y Small Business Fund (SBIR/STTR Programs). Through the fund, NIDA has invested in small businesses developing substance abuse products and services ranging from therapeutics, research tools, diagnostics, medical devices, and health IT to education. Victor previously held positions at ABL, RHT Consulting and Aeras Global. At ABL, a leading contract research and manufacturing organization, Victor oversaw a $100M preclinical development support contract with the National Institute of Allergies and Infectious Disease (NIAID) which focused on evaluating and moving the most promising biologics through product development and into Phase I clinical trials. At Aeras, Victor managed the company's R&D Adenovirus portfolio. This included developing internal lead vaccine candidates and co-developing next generation vaccines with industry partners including Okairos (Acquired by GSK), Crucell (Acquired by J&J) and Oxford University. His role also included creating and implementing a business development and branding strategy for the company's Contract Manufacturing Operations while contributing and participating in various committees and project groups which determine which vaccine candidates move from pre-clinical development to human clinical studies. In his free time, Victor enjoys being a father, a husband, working on a never ending honey to do list, and training his two dogs.

Craig Crews, Ph.D.

Dr. Crews is the Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology and holds joint appointments in the departments of Chemistry and Pharmacology at Yale University. He graduated from the U.Virginia with a B.A. in Chemistry and received his Ph.D. from Harvard University in Biochemistry. Dr. Crews has a foothold in both the academic and biotech arenas; on the faculty at Yale since 1995, his laboratory has pioneered the use of small molecules to control intracellular protein levels. In 2003, he co-founded Proteolix, Inc., whose proteasome inhibitor, Kyprolis™ recently received FDA approval for the treatment of multiple myeloma. Since Proteolix’s purchase by Onyx Pharmaceuticals in 2009, Dr. Crews has focused on a new drug development technology, which served as the founding intellectual property for his latest New Haven-based biotech venture, Arvinas, LLC. Currently, Dr. Crews serves on several editorial boards and is Editor of Cell Chemical Biology. In addition, he has received numerous awards and honors, including the 2013 CURE Entrepreneur of the Year Award, 2014 Ehrlich Award for Medicinal Chemistry, 2015 Yale Cancer Center Translational Research Prize, a NIH R35 Outstanding Investigator Award (2015) and the AACR Award for Chemistry in Cancer Research (2017).

Ayesha N. Khalid MD, MBA

Ayesha is a Board Certified ENT surgeon with over 15 years of experience in the healthcare industry. She recently completed her MBA at the MIT Sloan School of Management in the Sloan Fellows Program - a program focused on innovation and global leadership. Ayesha is a systems thinker and a healthcare innovation enthusiast. While at Sloan, Ayesha joined MIT H@cking Medicine to help promote disruptive thinking in healthcare. Prior to Sloan, Ayesha served on several Boards for medical organizations, performed cutting edge basic science and clinical research in the areas of inflammation and sinonasal disease. As a practicing clinician, understands the healthcare change process and the need to foster cross-disciplinary engagement. Ayesha serves as VP of Business Development at Doctella, a digital health tool out of Johns Hopkins that intends to change the surgical experience for patients. She is currently working to redesign the product to be delightful for patients. Ayesha is deeply committed to the patient voice in healthcare. She serves on the Board of Global Genes - a rare diseases patient advocacy organization. She has helped set up and lead their Medical and Scientific Advisory Board.

Lenka Fedorkova, Ph.D.

Dr. Fedorkova is CEO and Founder of bioPrime, LLC and a former Manager of SBIR/STTR Programs at National Institutes of Health. Dr. Fedorkova brings together her expertise in new company creation and funding as an SBIR/STTR Programs expert. She managed $780 million programs across 24 NIH Institutes and Centers, the CDC and FDA on funding strategies, funding opportunities and policy execution, and contract management. She has presented at over 100 public conferences, SBIR workshops, trade organization conferences, and federal events. She led development of technical assistance programs for small businesses with late-stage R&D and manufacturing needs. She has advised hundred’s US small businesses on application strategies and managed NIH’s flagship Commercialization Accelerator Program (CAP). She directed program framework and content development and grew the program's industry domain experts network. She evaluated over 800 business applications and selected over 380 SBIR/STTR awardees for CAP. She coached CAP companies on business plans, company management and growth strategies, fund-raising pitches, regulatory strategies, facilitated introductions, and go-to-market roadmapping. She reviewed 15 State applications for SBA’s FAST partnership grant program. She earned her Ph.D. in Neuroscience, at Kent State University.

Reena L. Pande, MD

As Chief Medical Officer of AbleTo, Reena serves as a passionate voice for the need to bridge the gaps between medical health and behavioral health. She spearheads AbleTo’s data analytics and outcomes research. In addition to her work at AbleTo, Dr. Pande is a practicing cardiologist at Brigham and Women’s Hospital in Boston, MA and Instructor at Harvard Medical School. Dr. Pande earned her undergraduate degree in Biology from Harvard University, her M.D. from Harvard Medical School, and a masters degree in Epidemiology from the Harvard School of Public Health. She completed her internship, residency training, and fellowship in Cardiovascular Disease and Vascular Medicine at Brigham and Women’s Hospital.

Greg Licholai, MD, MBA

Greg is President and Chief Scientific Officer at Castle Creek Pharmaceuticals. He is a member of the Executive Leadership Team and is responsible for all research and development activities, technical operations, medical affairs and the company’s scientific, regulatory, medical and clinical strategies. Previously he was founder and President of Elipdera, a Moderna Therapeutics venture company focused on developing messenger RNA therapies for rare genetic and metabolic diseases. He was a partner-level consultant at McKinsey & Co., where he ran a business line devoted to complex data analytics for pharmaceutical launches.

He was Senior Vice President for Real World and Late Stage Research at Quintiles, Inc. He was Chief Operating Officer at Proteostasis, a biotech company focused on developing chaperones for rare diseases. He was one of the original employees at Amicus Therapeutics, focused on pharmacological chaperones for rare diseases. He was also co-founder of Immunome, a biotech firm with a proprietary antibody platform for oncology. He was a venture capitalist at Domain Associates. He was director of Ventures and Business Development at Medtronic Neurological. He trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals. He was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health. He performed research in molecular genetics at Yale University and examined variants in hereditary blood disorders. He worked in molecular oncology at Rockefeller University.

Innovation To Impact

Contact us to learn more about the program